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Abstract
Background: The frequency of primary resistance to antibiotics in H. pylori isolates is increasing worldwide. In
Tunisia, there are limited data regarding the pattern of H. pylori antibiotic primary resistance.
Aim: To evaluate the primary resistance of H. pylori to clarithromycin, metronidazole and amoxicillin and to detect
the mutations involved in clarithromycin resistance.
Materials and methods: 273 strains isolated from adults and children were enrolled. The primary resistance to
clarithromycin, metronidazole and amoxicillin was evaluated by means of E-test minimal inhibitory concentration
(MIC). The real-time PCR using Scorpion primers was performed in all cases to assess clarithromycin primary
resistance and point mutations involved.
Results: No resistance to amoxicillin was detected. For adults, resistance to clarithromycin and metronidazole was
found respectively in 14.6% and 56.8%, and respectively in 18.8% and 25% in children. Overall, the rates of global
primary resistance to clarithromycin and metronidazole in Tunisia were respectively determined in 15.4% and 51.3%.
By the use of Scorpion PCR, the A2143G was the most frequent point mutation observed (88.1%), followed by the
A2142G (11.9%); the A2142C was not found and 18 of 42 patients (42.8%) were infected by both the resistant and
the susceptible genotype.
The association of clarithromycin resistance with gender was not statistically significant, but metronidazole resistant
strains were isolated more frequently in females (67.8%) than in males (32.2%) and the difference was significant.
As for gastroduodenal diseases, the difference between strains isolated from patients with peptic ulceration and
those with non peptic ulceration was not statistically significant. When about the distribution of resistant strains to
clarithromycin and metronidazole between the three Tunisian cities (Tunis, Menzel Bourguiba and Mahdia), the
difference was not statistically significant.
Conclusion: Local data regarding the primary resistance of H. pylori to clarithromycin, metronidazole and
amoxicillin and the main genetic mutation involved in clarithromycin resistance in vivo (A2143G) are necessary to
prove a clear need for a periodic evaluation of antibiotic consumption and new therapeutic strategies in Tunisia in
order to avoid the emergence of resistant strains.
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Helicobacter pylori (H. pylori) colonizes the human sto-
mach and it has emerged as an important pathogen in
the field of gastroenterology [1]. In Tunisia, his preva-
lence is average 90% in peptic ulcer [2]. Since 2005, the
Tunisian consensus had recommended the eradication of
H. pylori by a triple therapy which includes amoxicillin,
clarithromycin or metronidazole combined with proton
pump inhibitors (PPI) for 7 to 10 days [3]. Resistance to
these drugs reduces the success rate of treatment regi-
mens both in adults and children. Several studies have
demonstrated that primary resistance to clarithromycin is
a major predictive factor for therapeutic failure [4]; the
mechanism of this resistance decreased binding of the
antibiotic to the 50 S ribosomal subunit of the microor-
ganism and is due to three distinct point mutations
(A2142G, A2143G and A2142C) within the peptidyltrans-
ferase region encoded in domain V of the H. pylori bac-
terial 23 S rRNA gene [5]. The detection of mutations
was performed by the use of several real-time PCR meth-
ods [5-9]. Resistance to metronidazole is mainly due to
mutations in the rdxA gene encoding RdxA, an oxygen-
insensitive nitroreductase [10]. When about primary
resistance to metronidazole, conflicting results have been
reported on its impact in the treatment outcome [11].
Prevalence rates of primary clarithromycine and metroni-
dazole resistance were documented to be higher in devel-
oping countries than in industrialized ones [12,13].
Because of limited data on the resistance of H. pylori to
antibiotics in Tunisia, the aims of the present prospective
and multicentre study were: (i) to evaluate, by means of
E-test and Scorpion PCR the prevalence of primary resis-
tance to clarithromycin, and by means of E-test, the rates
of primary resistance to metronidazole and amoxicillin of
273 clinical strains isolated from children and adults, (ii)
to detect, for the first time in Tunisia, the mutations
involved in clarithromycin resistance by Scorpion PCR as
previously described [14].
Materials and methods
Materials
Patients and biopsies
In this study, the biopsy samples were taken over a 2
years-period (March 2005 to August 2007) from patients
referred for endoscopy at 6 different units of gastroen-
terology in three Tunisian cities (Tunis, Menzel Bour-
guiba and Mahdia). 273 patients had H. pylori positive
culture; 48 children (aged from 2 to 14 years; mean age
8.75 years) were distributed into gastritis in 47 cases
and one case of duodenal ulcer and, 225 adults (aged
from 18 to 88 years; mean age 38.3 years) in which 148
cases were defined as gastritis, 66 cases as duodenal
ulcer and gastric ulcer was observed in 11 cases. All
patients had not been treated before. Regarding the total
group, patients were distributed into gastritis in 195
cases, duodenal ulcer in 67 cases and gastric ulcer in 11
cases. The biopsy specimens were cultured on Columbia
agar plates supplemented with 10% horse blood and
Skirrow supplement (Oxoid, England) under microaero-
bic conditions for a maximum of 6 days as described by
Ben Mansour et al [15].
Setting
6 gastroenterology centers in 3 Tunisian cities: 1/Tunis
(Adult Units A and B in Rabta University Hospital,
Adult Gastroenterology Unit-Charles-Nicolle University
Hospital, and Paediatric Unit in Mongi-Slim University
Hospital); 2/Adult Gastroenterology Unit-Menzel Bour-
guiba Regional Hospital, and 3/Paediatric Unit-Mahdia
Regional Hospital, between March 2005 and August
2007.
DNA extraction
Genomic DNA was extracted with the QIAamp DNA
mini kit (Qiagen, Germany) according to the manufac-
turer’s instructions. The isolated DNA was eluted in 200
μl of 1 × TE buffer (10 mM Tris-HCl, 1 mM EDTA
[pH 8.0]) and stored at -20°C until use.
MIC determination
The inoculum was adjusted to an opacity equivalent to a
3-4 McFarland turbidity standard and was flooded on
Columbia agar plates containing 10% horse blood. The
E-test strip (AB Biodisk, Sweden) was placed on the
plate when it was dry and according to the instructions
of the manufacturer. Incubation was performed in a
microaerobic atmosphere for 48 to 72 hours at 37°C.
Strains were considered resistant to clarithromycin
when the MIC was ≥ 1 μg/ml for clarithromycin, ≥ 8
μg/ml for metronidazole and ≥ 0.5 μg/ml for amoxicil-
lin. These breakpoints were used on the basis of recom-
mendations as previously described [16].
Determination of point mutations in the 23 S rRNA gene of
H. pylori by Scorpion PCR
A 140-bp fragment of the 23 S rRNA gene of 273
strains of H. pylori was amplified by using primer 23SF2
and scorpion primers (Table 1). By using the Smart
Cycler 2.0 thermocycler, the PCR and hybridization
reactions were carried out in a volume of 25 μl with the
Premix Ex Taq (TAKARA, Shiga, Japan), 1 μlo f
extracted DNA from culture (approximately 200 ng), 0,1
μM of primer 23SF2, 0,14 μM of 23Ssc A2142G, 0,18
μM of 23Ssc A2143G, 0,1 μM of 23Ssc A2142C and
0,08 μM of 23Ssc WT. Amplification was performed
after a denaturation step (95°C for 15s) for 50 cycles,
annealing (55°C for 30s) and extension (72°C for 20s).
Four channels were reading the fluorescence for each
sample: 6-carboxyfluorescein [FAM], Texas red, Cy3
and Cy5. Data analysis was performed with Cepheid
Ben Mansour et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:22
http://www.ann-clinmicrob.com/content/9/1/22
Page 2 of 7Software (Cepheid, Sunny vale, CA). Four strains of
H. pylori were used as positive controls: one reference
strain (J99) with the wild type genotype/phenotype and
three Clarithromycin-resistant strains (HP 825, HP 225
and HP 222) with mutations determined by sequencing
of the 23 S rRNA gene (mutations A2142C, A2142G
and A2143G, respectively) [14].
Statistical analysis
Data were analyzed using X
2 test. A p value of < 0.05
was considered to be statistically significant.
Results
Detection of resistance to clarithromycin, metronidazole
and amoxicillin by E-test
In adults, the rates of primary resistance to clarithromy-
cin and metronidazole were determined respectively in
14.6% (33/225) and 56.8% (128/225) (Table 2). Primary
resistance to both clarithromycin and metronidazole was
found in 12.9% (29/225) of cases.
Among children, the primary resistance to clarithro-
mycin and to metronidazole was found respectively in 9
cases (18.8%) and in 12 cases (25%) of all 48 isolates
(Table 2). 8 strains (16.7%) were resistant to both clari-
thromycin and metronidazole.
Overall, the rates of global primary resistance to clari-
thromycin and metronidazole in Tunisia were respec-
tively determined in 15.4% (42 of 273) and in 51.3%
(140/273) and the rate of primary resistance to both
clarithromycin and metronidazole resistance was 13.6%
(37/273) in all studied strains. No resistance to amoxicil-
lin was found in the present study.
Detection of clarithromycin resistance and point
mutations conferring resistance to clarithromycin by
Scorpion PCR
In the present study, the primary resistance to clarithromy-
cin was also determined by means of Scorpion PCR as
reported elsewhere [14]. Resistance rate was 18.8% (9/48)
among children and 14.6% (33/225) in adults. We have not
found discrepancies between Scorpion PCR and E-test
methods. Mutations detected in only 42 clarithromycin-
resistant strains were summarized in Table 3. In 37 out of
the 42 studied strains, A2143G was detected (88.1%), with
21.4% (8/37) in children and 78.6% (29/37) in adults. The
A2142G was found in 11.9% (5/42) of strains; 2.3% was
detected in children and 9.6% in adults. The prevalence of
the two point mutations (A2143G and A2142G) did not
statistically differ between adults and children. The
A2142C mutation was not found in the present study and
was also less common. By using Scorpion PCR, we revealed
a presence of a mixed population in the same sample.
Interestingly, 18 of 42 subjects (42.8%) were infected by
both the susceptible and the resistant genotype.
The distribution of primary resistance to clarithromy-
cin and metronidazole according to gender and gastro-
duodenal diseases was shown in tables 4 and 5. As for
association of clarithromycin resistance with gender, no
significant difference in resistance was found (p > 0.05).
In contrast to clarithromycin, metronidazole resistant
Table 1 Scorpion primers and primer sequences
Oligonucleotide Mutations Sequence
23SF2 - 5’-TGCGAAATTCCTTGTCGG-3’
23SSc WT 5’-FAM AAGGTAGGTGAAAATTCCTCC
TACC BHQ1 HEG GGACCACGGGGTCTTT-3’
23Ssc A2143G 5’-Texas red AAGGTAGGTGAAAATTCCTCC
TACC BHQ2 HEG GGACCACGGGGTCTTT-3’
23Ssc A2142G 5’-Cy3 AAGGTAGGTGAAAATTCCTCC
TACC BHQ1 HEG GGACCACGGGGTCTTC-3’
23Ssc A2142C 5’-Cy5 AAGGTAGGTGAAAATTCCTCC
TACC BHQ1 HEG GGACCACGGGGTCTTG-3’
Table 2 Distribution of resistant strains to clarithromycin, metronidazole and amoxicillin among children, adults and a
total group
Clarithromycin Resistance Clarithromycin
Susceptible
Metronidazole
Resistance
Metronidazole
Susceptible
Amoxicilline
Resistance
Children
(N = 48)
9
(18.8%)
39
(81.2%)
12*
(25%)
36
(75%)
0
Adults
(N = 225)
33
(14.6%)
192
(85.4%)
128*
(56.8%)
97
(43.2%)
0
Total group
(N = 273)
42
(15.4%)
231
(84.6%)
140
(51.3%)
133
(48.7%)
0
*: a significant difference is present
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males (67.8% vs. 32.2%) and the difference was statisti-
cally significant (p < 0.05).
When about gastroduodenal diseases, no statistically
difference was found between strains isolated from
patients having peptic ulceration and those with non
peptic ulceration (p > 0.05).
As for the distribution of resistant strains to clari-
thromycin and metronidazole among the 3 Tunisian
cities (Table 6), the difference was not statistically
significant.
Discussion
In Tunisia, it’s very important to know the rates of pri-
mary resistance of H. pylori strains to clarithromycin,
metronidazole and amoxicillin, especially when antibio-
t i cr e s i s t a n c ei nH. pylori represents a serious public
health problem.
In adults, the rates of primary resistance to clarithro-
mycin and metronidazole were documented as 17.5% for
clarithromycin and 56% for metronidazole in 2002 [16].
There is a decrease in the rate of clarithromycin resis-
tance with 14.6% founded in our present study and a
slightly variation (56.8%) among metronidazole. In terms
of clarithromycin primary resistance, our prevalence
w o u l ds e e mh i g h e rt h a nt h a tc o m p u t e di nM a l a y s i a
(2.1%) [17], in Germany (2.2%) [18], in Canada (less
than 4%) [19], in Hong-Kong (4.5%) [20], in Korea
(5-6%) [21] and in one European multicentre study
(9.9%) [11]. This prevalence was almost similar to those
found in the USA (10-15%) [22], in France [23] but was
l o w e rt ot h a td e t e c t e di nI r a n( 1 7 % )[ 2 4 ] ,i nT u r k i s h
(27.6%) [25] and in one European study (43.5%) [26].
This difference in clarithromycin resistance rate between
several countries might be due to the prescription and
administration of this antibiotic. Indeed, since clarithro-
mycin is a widely used antimicrobial drug to treat infec-
tion in other organ systems than gastric tract, e.g.,
respiratory tract infections, the prevalence of clarithro-
mycin-resistant H. pylori is increasing continuously. No
differences in gastroduodenal diseases were seen
between patients with non peptic ulceration and those
with peptic ulceration (p > 0.05); the majority of studies
have mentioned no differences in prevalence in accor-
dance with disease status, but two studies did mention
such differences, and they concluded that duodenal
ulcer and non-ulcer dyspepsia patients should be mana-
ged differently in medical practice and considered inde-
pendently in eradication trials [27]. A2143G and
A2142G are the most prevalent point mutations, and
studies have claimed that these mutations play a major
role in clarithromycin resistance [5,23]. The prevalence
distribution of A2143G (78.6%) and A2142G (9.6%) in
adults was similar to those of patients in Taiwan study
and in a prospective multicentre survey carried out in
Europe [26]. We have not found the A2142C mutation
which is less common, e.g., it was found in 5 of 129
resistant strains [5].
As for metronidazole resistance, it is well known that
the prevalence of H. pylori is much higher in developing
countries (50-80%). Our prevalence was much higher
than that documented in an European multicentre study
and in Bulgaria where the rates were evaluated respec-
tively to 33.1% and 26.5% [11,28], but was lower to that
computed in Columbia (82%) [29], in Mexico (76.3%)
[30] and in Sweden (76%) [31]. In one Indian study, the
resistance to metronidazole was evaluated to 41.9% [32].
When regarding risk factors, we showed a higher primary
metronidazole resistance in female patients compared
with male ones, most likely due to the wide use of imida-
zoles for gynaecological infection. In agreement with data
presented by Glupczynski et al and Batnavala et al,
metronidazole resistant isolates were found significantly
more frequently in females than in males and in non-
E u r o p e a nn a t i v e st h a ni ns u b j e c t sb o r ni nE u r o p e a n
Table 3 Relationship between mutations conferring
clarithromycin resistance and pathologies
NPU* PU** Total
A2143G 28 (75.6%) 9 (24.4%) 37
A2142G 4 (80%) 1 (20%) 5
A2142C 0 0 0
NPU*: non peptic ulceration; PU**: peptic ulceration
Table 4 Relationship between the sex of patients and
resistance rates
Female Male Total
Clarithromycin resistance 26 (61.9%) 16 (38.1%) 42
Metronidazole resistance 95 (67.8%)* 45 (32.2%)* 140
*: a significant difference is present
Table 5 Relationship between the gastroduodenal
diseases and resistance rates
NPU PU Total
Clarithromycin resistance 32 (76.2%)** 10 (23.8%)** 42
Metronidazole resistance 96 (68.6%)** 44 (31.4%)** 140
**: the difference was not statistically significant
Table 6 Resistance rates among the 3 Tunisian cities
Tunis
(N =
181)
Menzel
Bourguiba
(N = 83)
Mahdia
(N = 9)
Total
(N =
273)
Clarithromycin
resistance
27** 12** 3 42
Metronidazole
resistance
95** 42** 3 140
**: the difference was not statistically significant
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Koletzko et al in their study where they found that
metronidazole was widely used in Africa and Asia to
treat parasitic diseases and gynaecological infections [35].
For children, the prevalence of clarithromycin primary
resistance (18.8%) was in agreement with a French one
where resistance to clarithromycin was detected in 18%
[36], and slightly lower than those founded in a European
prospective multicentre study and in Spain study where
the rates were evaluated respectively to 20% and 21.1%
[35,37], but more lower than that documented in an
Argentinean study (29.1%) [38]. Our prevalence was
lower than that reported by one previous Tunisian study
conducted with 46 treated children, where the suscept-
ibility testing was performed in 10 cases and where the
rates of resistance to clarithromycin and metronidazole
were respectively 30% and 90% [39].
When regarding the point mutations conferring resis-
tance to clarithromycin, we found that A2143G was
dominant followed by A2142G mutation, the A2142C
was not detected. Domingo et al [40] and Pina et al [9]
showed that the A2143G was more prevalent. De Fran-
cesco et al [41] reported that the A2143G was prevalent
in their study and concluded that this mutation reduces
markedly the eradication therapy efficacy. As for metro-
nidazole resistance, our prevalence (25%) was much
higher than that reported in 105 untreated children in
Bulgaria (16.2%) [30], but was slightly higher than that
documented from children in Argentina (23.9%), in
Spain (23%) [37] and in a European study (23%) [35].
Overall, the resistance rate for clarithromycin was lower
in adults than in children (14.6% vs. 18.8%), which points
to an acquisition of the resistance during childhood.
Indeed, macrolides are very often used nowadays to treat
respiratory infections in young children. By contrast, for
metronidazole the resistance rate was markedly higher in
adults than in children (56.8% vs. 25%). Our results were
not in agreement with those founded in a European study
[35], where the rates were very similar in adults and chil-
dren and where they concluded that the similar rate was
in favour of transmission of a resistant strain to the chil-
dren mostly from their mothers who widely used metroni-
dazole to treat gynaecologic infections. In contrast to
clarithromycin and metronidazole, no amoxicillin resis-
tance was observed; this finding was similar to those deter-
mined by Kim et al [21] and Wolle et al [18] in their
studies. This is despite the wide use of this antibiotic, both
alone and combined with clavulanic acid for the treatment
of respiratory tract infections or H. pylori infection in chil-
dren and adults. However, resistance to amoxicillin has
appeared in some countries with low frequencies and
could increase. The determination of resistant strains to
antibiotics by the E-test method has proven clinically
reliable except in the case of metronidazole for which the
E-test has a tendency to overestimate the presence of
resistance. The reason is not known, but it may be that a
pre-incubation of the media in an anaerobic atmosphere
has been shown a factor that increasing metronidazole
activity [42]. For that reason and for the lack of clinicobac-
teriological correlation, the Maastricht III 2005 Consensus
Report discourages routine metronidazole susceptibility
testing [43]. Then, further standardization should be per-
formed regarding the medium, the inoculum and the
growth atmosphere.
In conclusion, we believe that the widespread use of
macrolides in our country for the treatment of upper
respiratory tract infections could have an undesirable
outcome in the emergence of clarithromycin resistant
strains of H. pylori, reducing the success of therapy rate.
Moreover, the rate of annual consumption of antibiotics
in Tunisia was evaluated to 4% which is a risk factor for
increasing resistant strains to antibiotics; when regarding
macrolides, for example, the rate of consumption in
Tunisia exceed 4 millions units per year [44]. The clari-
thromycin resistance decreases the effectiveness of anti-
biotic therapy and is the main risk factor for treatment
failure: resistance reduces the efficacy of the first line
t h e r a p yb yu pt o7 0 %[ 2 4 ] .A m o n gt h eM a a s t r i c h tI I I
consensus report [43], treatment should achieve an era-
dication rate of ≥ 80%. The threshold of clarithromycin
resistance at which this antibiotic should not be used, or
a clarithromycin susceptibility test should be performed,
is 15-20% [43,45]. In Tunisia, physicians can continue
the prescription of clarithromycin as a treatment for
H. pylori i n f e c t i o ni na d u l t s ,i nw h o m1 4 . 6 %o fs t r a i n s
are resistant to this antibiotic, but in our paediatric
population where the rate of this resistance was 18.8%,
clarithromycin should not be used. Our study is the first
to show that A2143G is the main genetic mutation
involved in H. pylori clarithromycin resistance in vivo,
thus suggesting that new therapeutic strategies are
needed. When about metronidazole, we think that phy-
sicians might well refrain from using this antibiotic in
order to prevent the emergence of more resistant strains
especially because of the high rate of metronidazole
resistant strains in Tunisia. In one study performed in
North India, Bhatia et al [32] have concluded that imi-
dazole-based eradication regimens should be abandoned
in North India regardless of in vitro susceptibility results
(41.9%).
Because of the emergence of resistant strains in our
country, there is a clear need for a periodic evaluation
of antibiotic consumption, particularly of clarithromycin
in public hospitals and in private clinical sector.
There are no competing interests to declare for this
study.
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